Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | CBLB | Q13191 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554592 | 0.85 | ALDH1A1 (0.41) | ALDH1A1HSD17B10TRPV1P4HBCBLB | |
| SCHEMBL22627564 | 0.82 | ALDH1A1 (0.38) | ALDH1A1HSD17B10TRPV1P4HBCBLB | |
| SCHEMBL29793781 | 0.82 | CYP1A2 (0.39) | ALDH1A1HSD17B10P4HBCBLBPRMT5 | |
| SCHEMBL19423930 | 0.79 | TSHR (0.42) | ALDH1A1HSD17B10P4HBPRMT5 | |
| SCHEMBL19682359 | 0.72 | PKLR (0.33) | ALDH1A1HSD17B10TRPV1CBLBPRMT5 | |
| SCHEMBL20889271 | 0.72 | PKLR (0.33) | ALDH1A1HSD17B10TRPV1CBLBPRMT5 | |
| SCHEMBL20783232 | 0.72 | ALDH1A1 (0.33) | ALDH1A1HSD17B10PRMT5 | |
| SCHEMBL288904 | 0.71 | ALDH1A1 (0.46) | ALDH1A1HSD17B10TRPV1 | |
| SCHEMBL197613 | 0.71 | ALDH1A1 (0.45) | ALDH1A1HSD17B10PRMT5 | |
| SCHEMBL2088376 | 0.71 | ALDH1A1 (0.45) | ALDH1A1HSD17B10TRPV1P4HBPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | ALDH1A1 1103/4885HSD17B10 651/4885P2RX7 3672/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | ALDH1A1 1103/4885HSD17B10 651/4885P2RX7 3672/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | ALDH1A1 1103/4885HSD17B10 651/4885P2RX7 3672/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | ALDH1A1 1397/4885HSD17B10 1842/4885P2RX7 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.